DAVID SINE
- Type
- Physician · Allopathic & Osteopathic Physicians / Pediatrics
- Where
- EXETER, CA
- NPI
- 1124187018
- Received
- $2,564 in 16 records, 2019 to 2022 ($251 general, $2,313 research)
- As principal investigator
- $49,198 of research payments to others in 7 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 6 | $134 |
| 2021 | General payment | 3 | $63 |
| 2021 | Research payment | 2 | $1,619 |
| 2020 | General payment | 2 | $38 |
| 2020 | Research payment | 2 | $694 |
| 2019 | General payment | 1 | $15 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Eli Lilly and Company | 4 | $2,313 | 2020–2021 |
| GlaxoSmithKline, LLC. | 3 | $58 | 2021–2022 |
| Supernus Pharmaceuticals, Inc. | 2 | $44 | 2022 |
| Advanced Respiratory, Inc | 1 | $35 | 2021 |
| Novartis Pharmaceuticals Corporation | 1 | $32 | 2022 |
| Cranial Technologies, Inc | 1 | $21 | 2020 |
| SOBI, INC | 1 | $17 | 2020 |
| Merck Sharp & Dohme LLC | 1 | $15 | 2019 |
| Baxter Healthcare | 1 | $13 | 2022 |
| SANOFI PASTEUR INC. | 1 | $11 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 4 | $2,313 |
| Food and Beverage | 12 | $251 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-05-24 | GlaxoSmithKline, LLC. | $21 | Food and Beverage | In-kind items and services | BEXSERO Biological, VACCINES | 2022 | |
| 2022-05-20 | Supernus Pharmaceuticals, Inc. | $22 | Food and Beverage | Cash or cash equivalent | QELBREE Drug, PSYCHOLOGY | 2022 | |
| 2022-04-08 | Supernus Pharmaceuticals, Inc. | $22 | Food and Beverage | Cash or cash equivalent | QELBREE Drug, PSYCHOLOGY | 2022 | |
| 2022-02-16 | GlaxoSmithKline, LLC. | $21 | Food and Beverage | In-kind items and services | BEXSERO Biological, VACCINES | 2022 | |
| 2022-02-09 | Baxter Healthcare | $13 | Food and Beverage | In-kind items and services | Hillrom - Volara System Device, Airway Clearance Device | 2022 | |
| 2022-01-27 | Novartis Pharmaceuticals Corporation | $32 | Food and Beverage | In-kind items and services | LEQVIO Drug, CARDIOVASCULAR | 2022 | |
| 2021-06-11 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | BEXSERO Biological, VACCINES | 2021 | |
| 2021-06-04 | SANOFI PASTEUR INC. | $11 | Food and Beverage | In-kind items and services | VAXELIS Biological, Vaccines | 2021 | |
| 2021-03-30 | Advanced Respiratory, Inc | $35 | Food and Beverage | In-kind items and services | The Vest System Model 105 Home Care Device, Airway Clearance Device | 2021 | |
| 2021-02-10 | Eli Lilly and Company | $832 | Research payment | In-kind items and services | A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | 2021 | |
| 2021-01-29 | Eli Lilly and Company | $787 | Research payment | In-kind items and services | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREA | 2021 | |
| 2020-09-09 | SOBI, INC | $17 | Food and Beverage | In-kind items and services | SYNAGIS Drug, IMMUNOLOGY | 2020 | |
| 2020-07-02 | Eli Lilly and Company | $425 | Research payment | In-kind items and services | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREA | 2020 | |
| 2020-06-24 | Eli Lilly and Company | $268 | Research payment | In-kind items and services | A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | 2020 | |
| 2020-05-29 | Cranial Technologies, Inc | $21 | Food and Beverage | Cash or cash equivalent | Doc Band Device, Cranial Orthotic | 2020 | |
| 2019-03-19 | Merck Sharp & Dohme LLC | $15 | Food and Beverage | In-kind items and services | ROTATEQ Biological, VACCINE | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2022-11-01 | Eli Lilly and Company | CLINSCALE MANAGEMENT LLC | $2,545 | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREA | 2022 |
| 2021-05-31 | Eli Lilly and Company | San Miguel Medical | $154 | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREA | 2021 |
| 2021-05-28 | Eli Lilly and Company | CLINSCALE MANAGEMENT LLC | $16,442 | A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | 2021 |
| 2021-05-26 | Eli Lilly and Company | CLINSCALE MANAGEMENT LLC | $295 | A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | 2021 |
| 2021-05-26 | Eli Lilly and Company | CLINSCALE MANAGEMENT LLC | $255 | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREA | 2021 |
| 2021-05-11 | Eli Lilly and Company | CLINSCALE MANAGEMENT LLC | $29,473 | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREA | 2021 |
| 2020-07-10 | Eli Lilly and Company | CALIFORNIA RESEARCH TRIALS | $32 | A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Exeter, CA, county Tulare County, CA, state California; placed by its city name.
| Measure | Place (city or town) Exeter, CA | County Tulare County, CA | State California |
|---|---|---|---|
| Population B01003 | 10,258 | 478,693 | 39,287,377 |
| Population, 2020 census P1 | 10,321 | 473,117 | 39,538,223 |
| Median age B01002 | 34.8 | 32.1 | 37.9 |
| Under 18 B01001 | 28.7% | 29.8% | 22.0% |
| 65 and over B01001 | 13.9% | 11.9% | 15.7% |
| Households B11001 | 3,262 | 143,195 | 13,548,091 |
| Foreign born B05002 | 11.6% | 22.2% | 27.0% |
| Median household income B19013 | $75,769 | $71,300 | $99,122 |
| Median family income B19113 | $83,594 | $73,438 | $113,346 |
| Per capita income B19301 | $35,768 | $28,185 | $49,513 |
| Poverty rate B17001 | 14.2% | 17.9% | 12.0% |
| Unemployment rate B23025 | 9.6% | 9.3% | 6.6% |
| Civilian labor force B23025 | 4,374 | 215,454 | 20,068,466 |
| Mean commute (minutes) B08013 | 20.7 | 23.7 | 28.7 |
| Bachelor's degree or higher B15003 | 13.9% | 16.6% | 37.1% |
| Housing units B25001 | 3,515 | 154,202 | 14,644,735 |
| Owner-occupied B25003 | 54.7% | 58.5% | 55.9% |
| Renters B25003 | 45.3% | 41.5% | 44.1% |
| Median home value B25077 | $307,600 | $330,100 | $734,700 |
| Median gross rent B25064 | $1,286 | $1,280 | $2,036 |
| White, not Hispanic B03002 | 36.4% | 25.5% | 33.8% |
| Black B03002 | 0.1% | 1.3% | 5.2% |
| Hispanic or Latino B03002 | 58.5% | 66.6% | 40.2% |
| Asian B03002 | 3.5% | 3.5% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.4% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Exeter, CA.
Comments